Parvoviruses: Structure and infection

Future Virology

Volumn 7, Issue 3, 2012, Pages 253-278

  Halder, Sujata ^a   Ng, Robert ^a   Agbandje Mckenna, Mavis ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

capsid structure; gene therapy; parvoviruses; pathogenicity; tissue tropism

Indexed keywords

CELL SURFACE RECEPTOR; PROTEASOME; VIRUS DNA; VIRUS PROTEIN;

ADENO ASSOCIATED VIRUS; ALEUTIAN MINK DISEASE VIRUS; AMINO TERMINAL SEQUENCE; BOCAVIRUS; CELL INTERACTION; CELL MIGRATION; CELL NUCLEUS; CELL SURFACE; CONFOCAL MICROSCOPY; DNA PACKAGING; GENE EXPRESSION; GENE MUTATION; GENE REPLICATION; GENE TRANSLOCATION; HUMAN PARVOVIRUS B19; LIFE CYCLE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OPEN READING FRAME; PARVOVIRUS; PARVOVIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; VIRION; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS GENE; VIRUS MORPHOLOGY; X RAY CRYSTALLOGRAPHY;

MIRIDAE; PARVOVIRUS;

EID: 84858390096     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.12     Document Type: Review

References (245)

1. Berns KI, Parrish CR. Parvoviridae. In:Field's Virology Knipe DM, HowleyPM, Griffin DE etal. (Eds). Lippincott Williams & Wilkins, PA, USA, 2437-2478 (2007).
2. Bergoin M, Kleinschmidt J, Almendral JM etal. Ninth report of the International Committee on Taxonomy of Viruses. In:Virus Taxonomy King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ (Eds). Elsevier, The Netherlands, 405-425 (2011).
3. Parrish CR. Autonomous parvovirus variation and evolution. In:Parvoviruses Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR (Eds). Hodder Arnold, UK, 47-54 (2006).
4. Brown KE. The genus Erythrovirus. In:Parvoviruses Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR (Eds). Hodder Arnold, UK, 25-46 (2006).
5. Bowles DE, Rabinowitz JE, Samulski RJ. Thegenus Dependovirus. In:Parvoviruses Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR (Eds). Hodder Arnold, UK, 15-24 (2006).
6. Cotmore SF, Tattersall R. Structure and organization of the viral genome. In:Parvoviruses Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR (Eds). Hodder Arnold, UK, 73-94 (2006).
7. Chen KC, Shull BC, Moses EA, Lederman M, Stout ER, Bates RC. Complete nucleotide sequence and genome organization of bovine parvovirus. J. Virol. 60(3), 1085-1097 (1986).
8. Sun Y, Chen AY, Cheng F, Guan W, Johnson FB, Qiu J. Molecular characterization of infectious clones of the minute virus of canines reveals unique features of bocaviruses. J. Virol. 83(8), 3956-3967 (2009).
9. Lederman M, Bates RC, Stout ER. Invitro and invivo studies of bovine parvovirus proteins. J. Virol. 48(1), 10-17 (1983).
10. Johnson FB, Hoggan MD. Structural proteins of HADEN virus. Virology 51(1), 129-137 (1973).
11. Chapman MS, Agbandje-McKenna M. Atomic structures of viral particles. In:Parvoviruses Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR (Eds). Hodder Arnold, UK, 107-124 (2006).
12. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74(6), 2777-2785 (2000).
13. Basak S, Turner H. Infectious entry pathway for canine parvovirus. Virology 186(2), 368-376 (1992). n Provided the first evidence that successful parvoviral infection requires trafficking through low pH endosomal compartments.
14. Cotmore SF, Tattersall P. Parvoviral host range and cell entry mechanisms. Adv. Virus Res. 70, 183-232 (2007).
15. Duan D, Li Q, Kao AW, Yue Y, Pessin JE, Engelhardt JF. Dynamin is required for recombinant adeno-associated virus type 2 infection. J. Virol. 73(12), 10371-10376 (1999).
16. Parker JS, Parrish CR. Cellular uptake and infection by canine parvovirus involves rapid dynamin-regulated clathrin-mediated endocytosis, followed by slower intracellular trafficking. J. Virol. 74(4), 1919-1930 (2000).
17. Douar AM, Poulard K, Stockholm D, Danos O. Intracellular trafficking of adeno-associated virus vectors: Routing to the late endosomal compartment and proteasome degradation. J. Virol. 75(4), 1824-1833 (2001). n First report of the proteasomal degradation of adeno-associated virus (AAV) during its infectious life cycle.
18. Hansen J, Qing K, Srivastava A. Adeno-associated virus type2-mediated gene transfer: Altered endocytic processing enhances transduction efficiency in murine fibroblasts. J. Virol. 75(9), 4080-4090 (2001).
19. Parker JS, Murphy WJ, Wang D, O'Brien SJ, Parrish CR. Canine and feline parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells. J. Virol. 75(8), 3896-3902 (2001).
20. Ros C, Burckhardt CJ, Kempf C. Cytoplasmic trafficking of minute virus of mice: Low-pH requirement, routing to late endosomes, and proteasome interaction. J. Virol. 76(24), 12634-12645 (2002).
21. Vihinen-Ranta M, Kalela A, Makinen P, Kakkola L, Marjomaki V, Vuento M. Intracellular route of canine parvovirus entry. J. Virol. 72(1), 802-806 (1998).
22. Harbison CE, Chiorini JA, Parrish CR. Theparvovirus capsid odyssey: From the cell surface to the nucleus. Trends Microbiol. 16(5), 208-214 (2008).
23. Harbison CE, Lyi SM, Weichert WS, Parrish CR. Early steps in cell infection by parvoviruses: Host-specific differences in cell receptor binding but similar endosomal trafficking. J. Virol. 83(20), 10504-10514 (2009).
24. Hueffer K, Palermo LM, Parrish CR. Parvovirus infection of cells by using variantsof the feline transferrin receptor altering clathrin-mediated endocytosis, membrane domain localization, and capsid-binding domains. J. Virol. 78(11), 5601-5611 (2004).
25. Bantel-Schaal U, Hub B, Kartenbeck J. Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment. J. Virol. 76(5), 2340-2349 (2002). n First description of an alternative trafficking pathway for an AAV.
26. Boisvert M, Fernandes S, Tijssen P. Multiple pathways involved in porcine parvovirus cellular entry and trafficking toward the nucleus. J. Virol. 84(15), 7782-7792 (2010).
27. Johnson JS, Gentzsch M, Zhang L etal. AAV exploits subcellular stress associated with inflammation, endoplasmic reticulum expansion, and misfolded proteins in models of cystic fibrosis. PLoS Pathog. 7(5), E1002053 (2011). n The role of unfolded protein response in AAV trafficking.
28. Agbandje-McKenna M, Chapman, MS. Correlating structure with function in the viral capsid. In:Parvoviruses Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR (Eds). Hodder Arnold, UK, 125-140 (2006).
29. Agbandje-McKenna M, Kleinschmidt J. AAV capsid structure and cell interactions. Methods Mol. Biol. 807, 47-92 (2011). nn Detailed review of the properties and structural characteristics of AAV as it relates to its life cycle.
30. Zadori Z, Szelei J, Lacoste MC etal. A viral phospholipase A2 is required for parvovirus infectivity. Dev. Cell 1(2), 291-302 (2001). n Described the novel finding of an essential enzyme function, PLA2, encoded within the VP1 N-terminus of parvoviruses. This VP1 unique region has since been demonstrated to be essential for infectivity.
31. Sonntag F, Bleker S, Leuchs B, Fischer R, Kleinschmidt JA. Adeno-associated virus type2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J. Virol. 80(22), 11040-11054 (2006).
32. Wu P, Xiao W, Conlon T etal. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74(18), 8635-8647 (2000).
33. Grieger JC, Snowdy S, Samulski RJ. Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. J. Virol. 80(11), 5199-5210 (2006).
34. Johnson JS, Li C, Diprimio N, Weinberg MS, McCown TJ, Samulski RJ. Mutagenesis of adeno-associated virus type2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J. Virol. 84(17), 8888-8902 (2010).
35. Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6). Virology 420(1), 10-19 (2011).
36. Ng R, Govindasamy L, Gurda BL etal. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J. Virol. 84(24), 12945-12957 (2010).
37. Lerch TF, Xie Q, Chapman MS. The structure of adeno-associated virus serotype3B (AAV-3B): Insights into receptor binding and immune evasion. Virology 403(1), 26-36 (2010).
38. Nam HJ, Lane MD, Padron E etal. Structure of adeno-associated virus serotype8, a gene therapy vector. J. Virol. 81(22), 12260-12271 (2007).
39. Padron E, Bowman V, Kaludov N etal. Structure of adeno-associated virus type 4. J. Virol. 79(8), 5047-5058 (2005).
40. Walters RW, Agbandje-McKenna M, Bowman VD etal. Structure of adeno-associated virus serotype 5. J. Virol. 78(7), 3361-3371 (2004).
41. Xie Q, Bu W, Bhatia S etal. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl Acad. Sci. USA 99(16), 10405-10410 (2002).
42. Agbandje-McKenna M, Llamas-Saiz AL, Wang F, Tattersall P, Rossmann MG. Functional implications of the structure of the murine parvovirus, minute virus of mice. Structure 6(11), 1369-1381 (1998).
43. Llamas-Saiz AL, Agbandje-McKenna M, Wikoff WR, Bratton J, Tattersall P, Rossmann MG. Structure determination of minute virus of mice. Acta Crystallogr. D Biol. Crystallogr. 53(Pt1), 93-102 (1997).
44. Wu H, Keller W, Rossmann MG. Determination and refinement of the canine parvovirus empty-capsid structure. Acta Crystallogr. D Biol. Crystallogr. 49(Pt6), 572-579 (1993).
45. Agbandje M, McKenna R, Rossmann MG, Strassheim ML, Parrish CR. Structure determination of feline panleukopenia virus empty particles. Proteins 16(2), 155-171 (1993).
46. Kronenberg S, Bottcher B, Von Der Lieth CW, Bleker S, Kleinschmidt JA. A conformational change in the adeno-associated virus type2 capsid leads to the exposure of hidden VP1 N termini. J. Virol. 79(9), 5296-5303 (2005).
47. Kronenberg S, Kleinschmidt JA, Bottcher B. Electron cryo-microscopy and image reconstruction of adeno-associated virus type2 empty capsids. EMBO Rep. 2(11), 997-1002 (2001).
48. McKenna R, Olson NH, Chipman PR etal. Three-dimensional structure of Aleutian mink disease parvovirus: Implications for disease pathogenicity. J. Virol. 73(8), 6882-6891 (1999).
49. Govindasamy L, Padron E, McKenna R etal. Structurally mapping the diverse phenotypeof adeno-associated virus serotype 4. J. Virol. 80(23), 11556-11570 (2006). n Began the description of the regions of the AAV capsid that vary between the serotypes and began the functional annotation of these regions. They play essential roles in cell recognition, determine the serotype transduction efficiency and are the determinants of antigenic reactivity.
50. Simpson AA, Hebert B, Sullivan GM etal. The structure of porcine parvovirus: Comparison with related viruses. J. Mol. Biol. 315(5), 1189-1198 (2002).
51. Gurda BL, Parent KN, Bladek H etal. Human bocavirus capsid structure: Insights into the structural repertoire of the parvoviridae. J. Virol. 84(12), 5880-5889 (2010).
52. Kaufmann B, Simpson AA, Rossmann MG. The structure of human parvovirus B19. Proc. Natl Acad. Sci. USA 101(32), 11628-11633 (2004).
53. Kaufmann B, Chipman PR, Kostyuchenko VA, Modrow S, Rossmann MG. Visualization of the externalized VP2 N termini of infectious human parvovirus B19. J. Virol. 82(15), 7306-7312 (2008).
54. Tsao J, Chapman MS, Agbandje M etal. Thethree-dimensional structure of canine parvovirus and its functional implications. Science 251(5000), 1456-1464 (1991). n The first crystal structure solved for a member of Parvoviridae family at 3.25-Å resolution by the heavy atom phasing method, which provided the first starting model for the structure determination of other members.
55. Sonntag F, Kother K, Schmidt K etal. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J. Virol. 85(23), 12686-12697 (2011).
56. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: Physical, biological, and immunological characteristics. Proc. Natl Acad. Sci. USA 55(6), 1467-1474 (1966).
57. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science 149(3685), 754-756 (1965).
58. Carter BJ. Adeno-associated virus vectors and biology of gene delivery. In:Parvoviruses Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR (Eds). Hodder Arnold, UK, 497-498 (2006).
59. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 15(11), 858-863 (2008).
60. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 21(4), 583-593 (2008).
61. Coura Rdos S, Nardi NB. The state of the art of adeno-associated virus-based vectors in gene therapy. Virol. J. 4, 99 (2007).
62. Nathwani AC, Tuddenham EGD, Rangarajan S etal. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365(25), 2357-2365 (2011).
63. Stieger K, Cronin T, Bennett J, Rolling F. Adeno-associated virus mediated gene therapy for retinal degenerative diseases. Methods Mol. Biol. 807, 179-218 (2011).
64. Michelfelder S, Trepel M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv. Genet. 67, 29-60 (2009).
65. Boutin S, Monteilhet V, Veron P etal. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum. Gene Ther. 21(6), 704-712 (2010).
66. Gao G, Vandenberghe LH, Alvira MR etal. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78(12), 6381-6388 (2004).
67. Katano H, Afione S, Schmidt M, Chiorini JA. Identification of adeno-associated virus contamination in cell and virus stocks by PCR. Biotechniques 36(4), 676-680 (2004).
68. Qiu J, Cheng F, Pintel D. Molecular characterization of caprine adeno-associated virus (AAV-Go.1) reveals striking similarity to human AAV5. Virology 356(1-2), 208-216 (2006).
69. Arbetman AE, Lochrie M, Zhou S etal. Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties. J. Virol. 79(24), 15238-15245 (2005).
70. Lochrie MA, Tatsuno GP, Arbetman AE etal. Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5. Virology 353(1), 68-82 (2006).
71. Jacobson ER, Kopit W, Kennedy FA, Funk RS. Coinfection of a bearded dragon, Pogona vitticeps, with adenovirus-and dependovirus-like viruses. Vet. Pathol. 33(3), 343-346 (1996).
72. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16(6), 1073-1080 (2008).
73. Liu X, Luo M, Guo C, Yan Z, Wang Y, Engelhardt JF. Comparative biology of rAAV transduction in ferret, pig and human airway epithelia. Gene Ther. 14(21), 1543-1548 (2007).
74. Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM. Transduction efficiencies of novel AAV vectors in mouse airway epithelium invivo and human ciliated airway epithelium invitro. Mol. Ther. 17(2), 294-301 (2009).
75. Li W, Zhang L, Johnson JS etal. Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol. Ther. 17(12), 2067-2077 (2009).
76. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80(19), 9831-9836 (2006).
77. Bell CL, Vandenberghe LH, Bell P etal. The AAV9 receptor and its modification to improve invivo lung gene transfer in mice. J. Clin. Invest. 121(6), 2427-2435 (2011).
78. Di Pasquale G, Davidson BL, Stein CS etal. Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. 9(10), 1306-1312 (2003).
79. Di Pasquale G, Kaludov N, Agbandje-McKenna M, Chiorini JA. BAAV transcytosis requires an interaction with beta-1-4 linked-glucosamine and gp96. PLoS One 5(3), E9336 (2010).
80. Dickey DD, Excoffon KJ, Koerber JT etal. Enhanced sialic acid-dependent endocytosis explains the increased efficiency of infection of airway epithelia by a novel adeno-associated virus. J. Virol. 85(17), 9023-9030 (2011).
81. Kashiwakura Y, Tamayose K, Iwabuchi K etal. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J. Virol. 79(1), 609-614 (2005).
82. Ling C, Lu Y, Kalsi JK etal. Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum. Gene Ther. 21(12), 1741-1747 (2010).
83. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5(1), 71-77 (1999).
84. Seiler MP, Miller AD, Zabner J, Halbert CL. Adeno-associated virus types 5 and 6 use distinct receptors for cell entry. Hum. Gene Ther. 17(1), 10-19 (2006).
85. Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286(15), 13532-13540 (2011).
86. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type2 infection. Nat. Med. 5(1), 78-82 (1999).
87. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72(2), 1438-1445 (1998). n Identification of heparan sulfate proteoglycan as AAV2 receptor, which is now used as a purification reagent.
88. Walters RW, Yi SM, Keshavjee S etal. Binding of adeno-associated virus type5 to 2,3-linked sialic acid is required for gene transfer. J. Biol. Chem. 276(23), 20610-20616 (2001).
89. Weller ML, Amornphimoltham P, Schmidt M, Wilson PA, Gutkind JS, Chiorini JA. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat. Med. 16(6), 662-664 (2010).
90. Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ. Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 80(18), 9093-9103 (2006).
91. Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80(22), 11393-11397 (2006).
92. Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Adeno-associated virus type2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J. Virol. 80(18), 8961-8969 (2006).
93. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. Adeno-associated virus serotype4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75(15), 6884-6893 (2001).
94. Blackburn SD, Cline SE, Hemming JP, Johnson FB. Attachment of bovine parvovirus to O-linked alpha 2,3 neuraminic acid on glycophorin A. Arch. Virol. 150(7), 1477-1484 (2005).
95. O'Donnell J, Taylor KA, Chapman MS. Adeno-associated virus-2 and its primary cellular receptor -cryo-EM structure of a heparin complex. Virology 385(2), 434-443 (2009).
96. Levy HC, Bowman VD, Govindasamy L etal. Heparin binding induces conformational changes in adeno-associated virus serotype 2. J. Struct. Biol. 165(3), 146-156 (2009).
97. Schmidt M, Chiorini JA. Gangliosides are essential for bovine adeno-associated virus entry. J. Virol. 80(11), 5516-5522 (2006).
98. Opie SR, Warrington KH Jr, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77(12), 6995-7006 (2003).
99. Kern A, Schmidt K, Leder C etal. Identification of a heparin-binding motif on adeno-associated virus type2 capsids. J. Virol. 77(20), 11072-11081 (2003).
100. Excoffon KJ, Koerber JT, Dickey DD etal. Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc. NatlAcad. Sci. USA 106(10), 3865-3870 (2009).
101. Blackburn SD, Steadman RA, Johnson FB. Attachment of adeno-associated virus type3H to fibroblast growth factor receptor1. Arch. Virol. 151(3), 617-623 (2006).
102. Uhrig S, Coutelle O, Wiehe T, Perabo L, Hallek M, Buning H. Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. doi:10.1038/gt.2011.78 (2011) (Epub ahead of print).
103. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J. Clin. Invest. 105(11), 1573-1587 (2000).
104. Stahnke S, Lux K, Uhrig S etal. Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology 409(1), 77-83 (2011).
105. Bleker S, Sonntag F, Kleinschmidt JA. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J. Virol. 79(4), 2528-2540 (2005).
106. Bantel-Schaal U, Braspenning-Wesch I, Kartenbeck J. Adeno-associated virus type 5 exploits two different entry pathways in human embryo fibroblasts. J. Gen. Virol. 90(Pt2), 317-322 (2009).
107. Nam HJ, Gurda BL, McKenna R etal. Structural studies of adeno-associated virus serotype8 capsid transitions associated with endosomal trafficking. J. Virol. 85(22), 11791-11799 (2011). n Structural insights into low pH-mediated capsid conformation transitions that likely prime the AAV capsid for subsequent events in trafficking and uncoating in the host nucleus.
108. Olia AS, Prevelige PE Jr, Johnson JE, Cingolani G. Three-dimensional structure ofa viral genome-delivery portal vertex. Nat. Struct. Mol. Biol. 18(5), 597-603 (2011).
109. Ros C, Baltzer C, Mani B, Kempf C. Parvovirus uncoating invitro reveals a mechanism of DNA release without capsid disassembly and striking differences in encapsidated DNA stability. Virology 345(1), 137-147 (2006).
110. Zhong L, Li B, Jayandharan G etal. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381(2), 194-202 (2008).
111. Zhong L, Li B, Mah CS etal. Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl Acad. Sci. USA 105(22), 7827-7832 (2008).
112. Xiao W, Warrington KH Jr, Hearing P, Hughes J, Muzyczka N. Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2. J. Virol. 76(22), 11505-11517 (2002).
113. Hansen J, Qing K, Srivastava A. Infection of purified nuclei by adeno-associated virus 2. Mol. Ther. 4(4), 289-296 (2001).
114. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T, Engelhardt JF. Endocytosis and nuclear trafficking of adeno-associated virus type2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J. Virol. 74(19), 9184-9196 (2000).
115. Johnson JS, Samulski RJ. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J. Virol. 83(6), 2632-2644 (2009).
116. Lux K, Goerlitz N, Schlemminger S etal. Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking. J. Virol. 79(18), 11776-11787 (2005).
117. Cotmore SF, Tattersall R. A rolling-hairpin strategy: Basic mechanism of DNA replication in the parvoviruses. In:Parvoviruses. Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR (Eds). Hodder Arnold, UK, 171-188 (2006).
118. Walker SL, Wonderling RS, Owens RA. Mutational analysis of the adeno-associated virus type2 Rep68 protein helicase motifs. J. Virol. 71(9), 6996-7004 (1997).
119. Mccarty DM, Ni TH, Muzyczka N. Analysis of mutations in adeno-associated virus Rep protein invivo and invitro. J. Virol. 66(7), 4050-4057 (1992).
120. Chejanovsky N, Carter BJ. Mutation of a consensus purine nucleotide binding site in the adeno-associated virus rep gene generates a dominant negative phenotype for DNA replication. J. Virol. 64(4), 1764-1770 (1990).
121. King JA, Dubielzig R, Grimm D, Kleinschmidt JA. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J. 20(12), 3282-3291 (2001).
122. Ni TH, Zhou X, McCarty DM, Zolotukhin I, Muzyczka N. Invitro replication of adeno-associated virus DNA. J. Virol. 68(2), 1128-1138 (1994).
123. Dubielzig R, King JA, Weger S, Kern A, Kleinschmidt JA. Adeno-associated virus type2 protein interactions: Formation of pre-encapsidation complexes. J. Virol. 73(11), 8989-8998 (1999).
124. Bleker S, Pawlita M, Kleinschmidt JA. Impact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging. J. Virol. 80(2), 810-820 (2006).
125. Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl Acad. Sci. USA 107(22), 10220-10225 (2010). n Reports the discovery of an assembly-activating protein that is essential for capsid assembly.
126. Diprimio N, Asokan A, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Surface loop dynamics in adeno-associated virus capsid assembly. J. Virol. 82(11), 5178-5189 (2008).
127. Chejanovsky N, Carter BJ. Mutagenesis of an AUG codon in the adeno-associated virus rep gene: Effects on viral DNA replication. Virology 173(1), 120-128 (1989).
128. Collaco RF, Kalman-Maltese V, Smith AD, Dignam JD, Trempe JP. A biochemical characterization of the adeno-associated virus Rep40 helicase. J. Biol. Chem. 278(36), 34011-34017 (2003).
129. Owens RA, Weitzman MD, Kyostio SR, Carter BJ. Identification of a DNA-binding domain in the amino terminus of adeno-associated virus Rep proteins. J. Virol. 67(2), 997-1005 (1993).
130. Yang Q, Trempe JP. Analysis of the terminal repeat binding abilities of mutant adeno-associated virus replication proteins. J. Virol. 67(7), 4442-4447 (1993).
131. Mccarty DM, Pereira DJ, Zolotukhin I, Zhou X, Ryan JH, Muzyczka N. Identification of linear DNA sequences that specifically bind the adeno-associated virus Rep protein. J. Virol. 68(8), 4988-4997 (1994).
132. Yoon-Robarts M, Linden RM. Identification of active site residues of the adeno-associated virus type2 Rep endonuclease. J. Biol. Chem. 278(7), 4912-4918 (2003).
133. Mansilla-Soto J, Yoon-Robarts M, Rice WJ, Arya S, Escalante CR, Linden RM. DNA structure modulates the oligomerization properties of the AAV initiator protein Rep68. PLoS Pathog. 5(7), E1000513 (2009).
134. Timpe J, Bevington J, Casper J, Dignam JD, Trempe JP. Mechanisms of adeno-associated virus genome encapsidation. Curr. Gene Ther. 5(3), 273-284 (2005).
135. Herzog RW. Immune responses to AAV capsid: Are mice not humans after all? Mol. Ther. 15(4), 649-650 (2007).
136. Sabatino DE, Mingozzi F, Hui DJ etal. Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol. Ther. 12(6), 1023-1033 (2005).
137. Mays LE, Wilson JM. Identification of the murine AAVrh32.33 capsid-specific CD8+ T cell epitopes. J. Gene Med. 11(12), 1095-1102 (2009).
138. Li C, Hirsch M, Diprimio N etal. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector invivo. J. Virol. 83(13), 6817-6824 (2009).
139. Manno CS, Pierce GF, Arruda VR etal. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12(3), 342-347 (2006).
140. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: A continued challenge. Gene Ther. 15(11), 808-816 (2008).
141. Wobus CE, Hugle-Dorr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA. Monoclonal antibodies against the adeno-associated virus type2 (AAV-2) capsid: Epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74(19), 9281-9293 (2000). n This antibody epitope mapping study identified immunodominant AAV2 capsid regions and provided reagents that have impacted the field with respect to further immunological studies of AAVs.
142. Lochrie MA, Tatsuno GP, Christie B etal. Mutations on the external surfaces of adeno-associated virus type2 capsids that affect transduction and neutralization. J. Virol. 80(2), 821-834 (2006). n An exhaustive mutagenesis study of AAV2 capsid surface-exposed residues to elucidate the role played by the capsid in various steps of viral life cycle, including receptor attachment and antibody recogntion.
143. Kuck D, Kern A, Kleinschmidt JA. Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. J. Virol. Methods 140(1-2), 17-24 (2007).
144. Harbison CE, Weichert WS, Gurda BL, Chiorini JA, Agbandje-McKenna M, Parrish CR. Examining the cross-reactivity and neutralization mechanisms of a panel of monoclonal antibodies against adeno-associated virus serotypes 1 and 5. J. Gen. Virol. 93(Pt2), 347-355 (2012).
145. Weitzman MD. The parvovirus life cycle: An introduction to molecular interactions important for infection. In:Parvoviruses Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR (Eds). Hodder Arnold, UK, 143-156 (2006).
146. Tattersall P. The evolution of parvovirus taxonomy. In:Parvoviruses. Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR (Eds). Hodder Arnold, UK, 5-14 (2006).
147. Bloom ME, Kanno H, Mori S, Wolfinbarger JB. Aleutian mink disease: Puzzles and paradigms. Infect. Agents Dis. 3(6), 279-301 (1994).
148. Dworak LJ, Wolfinbarger JB, Bloom ME. Aleutian mink disease parvovirus infection of K562 cells is antibody-dependent and is mediated via an Fc(gamma)RII receptor. Arch. Virol. 142(2), 363-373 (1997).
149. Bloom ME, Best SM, Hayes SF etal. Identification of Aleutian mink disease parvovirus capsid sequences mediating antibody-dependent enhancement of infection, virus neutralization, and immune complex formation. J. Virol. 75(22), 11116-11127 (2001).
150. Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J. Gen. Virol. 88(Pt 2), 365-375 (2007).
151. Munakata Y, Kato I, Saito T, Kodera T, Ishii KK, Sasaki T. Human parvovirus B19 infection of monocytic cell line U937 and antibody-dependent enhancement. Virology 345(1), 251-257 (2006).
152. Manteufel J, Truyen U. Animal bocaviruses: A brief review. Intervirology 51(5), 328-334 (2008).
153. Allander T. Human bocavirus. J. Clin. Virol. 41(1), 29-33 (2008).
154. Allander T, Jartti T, Gupta S etal. Human bocavirus and acute wheezing in children. Clin. Infect. Dis. 44(7), 904-910 (2007).
155. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl Acad. Sci. USA 102(36), 12891-12896 (2005).
156. Arthur JL, Higgins GD, Davidson GP, Givney RC, Ratcliff RM. A novel bocavirus associated with acute gastroenteritis in Australian children. PLoS Pathog. 5(4), E1000391 (2009).
157. Lindner J, Karalar L, Schimanski S, Pfister H, Struff W, Modrow S. Clinical and epidemiological aspects of human bocavirus infection. J. Clin. Virol. 43(4), 391-395 (2008).
158. Vicente D, Cilla G, Montes M, Perez-Yarza EG, Perez-Trallero E. Human bocavirus, a respiratory and enteric virus. Emerg. Infect. Dis. 13(4), 636-637 (2007).
159. Chow BD, Ou Z, Esper FP. Newly recognized bocaviruses (HBoV, HBoV2) in children and adults with gastrointestinal illness in the United States. J. Clin. Virol. 47(2), 143-147 (2010).
160. Anderson MJ, Jones SE, Fisher-Hoch SP etal. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet 1(8338), 1378 (1983).
161. Katz VL, Chescheir NC, Bethea M. Hydrops fetalis from B19 parvovirus infection. J. Perinatol. 10(4), 366-368 (1990).
162. Naides SJ. Infection with Parvovirus B19. Curr. Infect. Dis. Rep. 1(3), 273-278 (1999).
163. Smith-Whitley K, Zhao H, Hodinka RL etal. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood 103(2), 422-427 (2004).
164. Young NS, Brown KE. Parvovirus B19. N. Engl. J. Med. 350(6), 586-597 (2004).
165. Green SW, Malkovska I, O'Sullivan MG, Brown KE. Rhesus and pig-tailed macaque parvoviruses: Identification of two new members of the erythrovirus genus in monkeys. Virology 269(1), 105-112 (2000).
166. Segovia JC, Gallego JM, Bueren JA, Almendral JM. Severe leukopenia and dysregulated erythropoiesis in SCID mice persistently infected with the parvovirus minute virus of mice. J. Virol. 73(3), 1774-1784 (1999).
167. Kimsey PB, Engers HD, Hirt B, Jongeneel CV. Pathogenicity of fibroblast-and lymphocyte-specific variants of minute virus of mice. J. Virol. 59(1), 8-13 (1986).
168. Tattersall P, Bratton J. Reciprocal productive and restrictive virus-cell interactions of immunosuppressive and prototype strains of minute virus of mice. J. Virol. 46(3), 944-955 (1983).
169. Spegelaere P, Van Hille B, Spruyt N, Faisst S, Cornelis JJ, Rommelaere J. Initiation of transcription from the minute virus of mice P4 promoter is stimulated in rat cells expressing a c-Ha-ras oncogene. J. Virol. 65(9), 4919-4928 (1991).
170. Paglino J, Tattersall P. The parvoviral capsid controls an intracellular phase of infection essential for efficient killing of stepwise-transformed human fibroblasts. Virology 416(1-2), 32-41 (2011).
171. Abschuetz A, Kehl T, Geibig R, Leuchs B, Rommelaere J, Regnier-Vigouroux A. Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells. Cell Tissue Res. 325(3), 423-436 (2006).
172. Kontou M, Govindasamy L, Nam HJ etal. Structural determinants of tissue tropism and invivo pathogenicity for the parvovirus minute virus of mice. J. Virol. 79(17), 10931-10943 (2005).
173. Fox JM, Bloom ME. Identification of a cell surface protein from Crandell feline kidney cells that specifically binds Aleutian mink disease parvovirus. J. Virol. 73(5), 3835-3842 (1999).
174. Thacker TC, Johnson FB. Binding of bovine parvovirus to erythrocyte membrane sialylglycoproteins. J. Gen. Virol. 79(Pt9), 2163-2169 (1998).
175. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: Cellular receptor for B19 parvovirus. Science 262(5130), 114-117 (1993).
176. Weigel-Kelley KA, Yoder MC, Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: Requirement of functional activation of beta1 integrin for viral entry. Blood 102(12), 3927-3933 (2003).
177. Munakata Y, Saito-Ito T, Kumura-Ishii K etal. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 106(10), 3449-3456 (2005).
178. Cotmore SF, Tattersall P. The autonomously replicating parvoviruses of vertebrates. Adv. Virus Res. 33, 91-174 (1987). n The first comprehensive review on the autonomous parvoviruses.
179. Kannagi R. Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression -the Warburg effect revisited. Glycoconj. J. 20(5), 353-364 (2004).
180. Nam HJ, Gurda-Whitaker B, Gan WY etal. Identification of the sialic acid structures recognized by minute virus of mice and the role of binding affinity in virulence adaptation. J. Biol. Chem. 281(35), 25670-25677 (2006).
181. Sato C, Fukuoka H, Ohta K etal. Frequent occurrence of pre-existing alpha 2 ->8-linked disialic and oligosialic acids with chain lengths up to 7 Sia residues in mammalian brain glycoproteins. Prevalence revealed by highly sensitive chemical methods and anti-di-, oligo-, and poly-Sia antibodies specific for defined chain lengths. J. Biol. Chem. 275(20), 15422-15431 (2000).
182. Hueffer K, Parker JS, Weichert WS, Geisel RE, Sgro JY, Parrish CR. The natural host range shift and subsequent evolution of canine parvovirus resulted from virus-specific binding to the canine transferrin receptor. J. Virol. 77(3), 1718-1726 (2003).
183. Barbis DP, Chang SF, Parrish CR. Mutations adjacent to the dimple of the canine parvovirus capsid structure affect sialic acid binding. Virology 191(1), 301-308 (1992).
184. Bloom ME, Alexandersen S, Perryman S, Lechner D, Wolfinbarger JB. Nucleotide sequence and genomic organization of Aleutian mink disease parvovirus (ADV): Sequence comparisons between a nonpathogenic and a pathogenic strain of ADV. J. Virol. 62(8), 2903-2915 (1988).
185. Stevenson MA, Fox JM, Wolfinbarger JB, Bloom ME. Effect of a valine residue at codon 352 of the VP2 capsid protein on invivo replication and pathogenesis of Aleutian disease parvovirus in mink. Am. J. Vet. Res. 62(10), 1658-1663 (2001).
186. Govindasamy L, Hueffer K, Parrish CR, Agbandje-McKenna M. Structures of host range-controlling regions of the capsids of canine and feline parvoviruses and mutants. J. Virol. 77(22), 12211-12221 (2003).
187. Hueffer K, Govindasamy L, Agbandje-McKenna M, Parrish CR. Combinations of two capsid regions controlling canine host range determine canine transferrin receptor binding by canine and feline parvoviruses. J. Virol. 77(18), 10099-10105 (2003).
188. Hafenstein S, Palermo LM, Kostyuchenko VA etal. Asymmetric binding of transferrin receptor to parvovirus capsids. Proc. Natl Acad. Sci. USA 104(16), 6585-6589 (2007).
189. Chipman PR, Agbandje-McKenna M, Kajigaya S etal. Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor. Proc. Natl Acad. Sci. USA 93(15), 7502-7506 (1996). n First cryoreconstruction study that enabled the visualization of a capsid-receptor interaction.
190. Kaufmann B, Baxa U, Chipman PR, Rossmann MG, Modrow S, Seckler R. Parvovirus B19 does not bind to membrane-associated globoside invitro. Virology 332(1), 189-198 (2005).
191. Lopez-Bueno A, Rubio MP, Bryant N, McKenna R, Agbandje-McKenna M, Almendral JM. Host-selected amino acid changes at the sialic acid binding pocket of the parvovirus capsid modulate cell binding affinity and determine virulence. J. Virol. 80(3), 1563-1573 (2006). n First crystal structure of parvovirus-receptor complex identifying a sialic acid binding pocket.
192. Farr GA, Zhang LG, Tattersall P. Parvoviral virions deploy a capsid-tethered lipolytic enzyme to breach the endosomal membrane during cell entry. Proc. Natl Acad. Sci. USA 102(47), 17148-17153 (2005).
193. Mani B, Baltzer C, Valle N, Almendral JM, Kempf C, Ros C. Low pH-dependent endosomal processing of the incoming parvovirus minute virus of mice virion leads to externalization of the VP1 N-terminal sequence (N-VP1), N-VP2 cleavage, and uncoating of the full-length genome. J. Virol. 80(2), 1015-1024 (2006).
194. Farr GA, Cotmore SF, Tattersall P. VP2 cleavage and the leucine ring at the base of the fivefold cylinder control pH-dependent externalization of both the VP1 N terminus and the genome of minute virus of mice. J. Virol. 80(1), 161-171 (2006).
195. Farr GA, Tattersall P. A conserved leucine that constricts the pore through the capsid fivefold cylinder plays a central role in parvoviral infection. Virology 323(2), 243-256 (2004).
196. Rosenfeld SJ, Yoshimoto K, Kajigaya S etal. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J. Clin. Invest. 89(6), 2023-2029 (1992).
197. Ros C, Gerber M, Kempf C. Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J. Virol. 80(24), 12017-12024 (2006).
198. Boschetti N, Niederhauser I, Kempf C, Stuhler A, Lower J, Blumel J. Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 44(7), 1079-1086 (2004).
199. Yan Z, Zak R, Luxton GW, Ritchie TC, Bantel-Schaal U, Engelhardt JF. Ubiquitination of both adeno-associated virus type2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J. Virol. 76(5), 2043-2053 (2002).
200. Ros C, Kempf C. The ubiquitin-proteasome machinery is essential for nuclear translocation of incoming minute virus of mice. Virology 324(2), 350-360 (2004).
201. Suikkanen S, Aaltonen T, Nevalainen M etal. Exploitation of microtubule cytoskeleton and dynein during parvoviral traffic toward the nucleus. J. Virol. 77(19), 10270-10279 (2003).
202. Lombardo E, Ramirez JC, Garcia J, Almendral JM. Complementary roles of multiple nuclear targeting signals in the capsid proteins of the parvovirus minute virus of mice during assembly and onset of infection. J. Virol. 76(14), 7049-7059 (2002).
203. Vihinen-Ranta M, Wang D, Weichert WS, Parrish CR. The VP1 N-terminal sequence of canine parvovirus affects nuclear transport of capsids and efficient cell infection. J. Virol. 76(4), 1884-1891 (2002).
204. Cohen S, Marr AK, Garcin P, Pante N. Nuclear envelope disruption involving host caspases plays a role in the parvovirus replication cycle. J. Virol. 85(10), 4863-4874 (2011).
205. Cohen S, Behzad AR, Carroll JB, Pante N. Parvoviral nuclear import: Bypassing the host nuclear-transport machinery. J. Gen. Virol. 87(Pt11), 3209-3213 (2006).
206. Cohen S, Pante N. Pushing the envelope: Microinjection of minute virus of mice into Xenopus oocytes causes damage to the nuclear envelope. J. Gen. Virol. 86(Pt 12), 3243-3252 (2005).
207. Cotmore SF, Hafenstein S, Tattersall P. Depletion of virion-associated divalent cations induces parvovirus minute virus of mice to eject its genome in a 3'-to-5' direction from an otherwise intact viral particle. J. Virol. 84(4), 1945-1956 (2010).
208. Cotmore SF, D'Abramo AM Jr, Ticknor CM, Tattersall P. Controlled conformational transitions in the MVM virion expose the VP1 N-terminus and viral genome without particle disassembly. Virology 254(1), 169-181 (1999).
209. Vanacker J-M, Rommelaere J. Non-structural proteins of autonomous parvoviruses: From cellular effects to molecular mechanisms. Semin. Virol. 6, 291-297 (1995).
210. Cotmore SF, D'Abramo AM Jr, Carbonell LF, Bratton J, Tattersall P. The NS2 polypeptide of parvovirus MVM is required for capsid assembly in murine cells. Virology 231(2), 267-280 (1997).
211. Eichwald V, Daeffler L, Klein M, Rommelaere J, Salome N. The NS2 proteins of parvovirus minute virus of mice are required for efficient nuclear egress of progeny virions in mouse cells. J. Virol. 76(20), 10307-10319 (2002).
212. Naeger LK, Salome N, Pintel DJ. NS2 is required for efficient translation of viral mRNA in minute virus of mice-infected murine cells. J. Virol. 67(2), 1034-1043 (1993).
213. Legrand C, Rommelaere J, Caillet-Fauquet P. MVM(p) NS-2 protein expression is required with NS-1 for maximal cytotoxicity in human transformed cells. Virology 195(1), 149-155 (1993).
214. Cotmore SF, Tattersall P. Parvovirus DNA replication. Cold Spring Harbor Lab. 799-813 (1996).
215. Riolobos L, Reguera J, Mateu MG, Almendral JM. Nuclear transport of trimeric assembly intermediates exerts a morphogenetic control on the icosahedral parvovirus capsid. J. Mol. Biol. 357(3), 1026-1038 (2006).
216. Lombardo E, Ramirez JC, Agbandje-McKenna M, Almendral JM. A beta-stranded motif drives capsid protein oligomers of the parvovirus minute virus of mice into the nucleus for viral assembly. J. Virol. 74(8), 3804-3814 (2000).
217. Cotmore SF, Tattersall P. A genome-linked copy of the NS-1 polypeptide is located on the outside of infectious parvovirus particles. J. Virol. 63(9), 3902-3911 (1989).
218. Reguera J, Grueso E, Carreira A, Sanchez-Martinez C, Almendral JM, Mateu MG. Functional relevance of amino acid residues involved in interactions with ordered nucleic acid in a spherical virus. J. Biol. Chem. 280(18), 17969-17977 (2005).
219. Chen KC, Shull BC, Lederman M, Stout ER, Bates RC. Analysis of the termini of the DNA of bovine parvovirus: Demonstration of sequence inversion at the left terminus and its implication for the replication model. J. Virol. 62(10), 3807-3813 (1988).
220. Cotmore SF, Tattersall P. Encapsidation of minute virus of mice DNA: Aspects of the translocation mechanism revealed by the structure of partially packaged genomes. Virology 336(1), 100-112 (2005).
221. Cotmore SF, Tattersall P. Genome packaging sense is controlled by the efficiency of the nick site in the right-end replication origin of parvoviruses minute virus of mice and LuIII. J. Virol. 79(4), 2287-2300 (2005).
222. Cotmore SF, Tattersall P. Mutations at the base of the icosahedral five-fold cylinders of minute virus of mice induce 3'-to-5' genome uncoating and critically impair entry functions. J. Virol. 86(1), 69-80 (2012).
223. Plevka P, Hafenstein S, Li L etal. Structure of a packaging-defective mutant of minute virus of mice indicates that the genome is packaged via a pore at a 5-fold axis. J. Virol. 85(10), 4822-4827 (2011).
224. Lang SI, Boelz S, Stroh-Dege AY, Rommelaere J, Dinsart C, Cornelis JJ. The infectivity and lytic activity of minute virus of mice wild-type and derived vector particles are strikingly different. J. Virol. 79(1), 289-298 (2005).
225. Kestler J, Neeb B, Struyf S etal. cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum. Gene Ther. 10(10), 1619-1632 (1999).
226. Maroto B, Ramirez JC, Almendral JM. Phosphorylation status of the parvovirus minute virus of mice particle: Mapping and biological relevance of the major phosphorylation sites. J. Virol. 74(23), 10892-10902 (2000).
227. Maroto B, Valle N, Saffrich R, Almendral JM. Nuclear export of the nonenveloped parvovirus virion is directed by an unordered protein signal exposed on the capsid surface. J. Virol. 78(19), 10685-10694 (2004).
228. Hernando E, Llamas-Saiz AL, Foces-Foces C etal. Biochemical and physical characterization of parvovirus minute virus of mice virus-like particles. Virology 267(2), 299-309 (2000).
229. Kanno H, Wolfinbarger JB, Bloom ME. Aleutian mink disease parvovirus infection of mink macrophages and human macrophage cell line U937: Demonstration of antibody-dependent enhancement of infection. J. Virol. 67(12), 7017-7024 (1993).
230. Aasted B, Alexandersen S, Christensen J. Vaccination with Aleutian mink disease parvovirus (AMDV) capsid proteins enhances disease, while vaccination with the major non-structural AMDV protein causes partial protection from disease. Vaccine 16(11-12), 1158-1165 (1998).
231. Bloom ME, Martin DA, Oie KL etal. Expression of Aleutian mink disease parvovirus capsid proteins in defined segments: Localization of immunoreactive sites and neutralizing epitopes to specific regions. J. Virol. 71(1), 705-714 (1997).
232. Porter DD, Larsen AE, Porter HG. The pathogenesis of Aleutian disease of mink. II. Enhancement of tissue lesions following the administration of a killed virus vaccine or passive antibody. J. Immunol. 109(1), 1-7 (1972).
233. Sato H, Hirata J, Kuroda N, Shiraki H, Maeda Y, Okochi K. Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodies. J. Virol. 65(10), 5485-5490 (1991).
234. Sato H, Hirata J, Furukawa M etal. Identification of the region including the epitope for a monoclonal antibody which can neutralize human parvovirus B19. J. Virol. 65(4), 1667-1672 (1991).
235. Brown KE, Cohen BJ. Haemagglutination by parvovirus B19. J. Gen. Virol. 73(Pt8), 2147-2149 (1992).
236. Saikawa T, Anderson S, Momoeda M, Kajigaya S, Young NS. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1unique and VP1-VP2 junction regions. J. Virol. 67(6), 3004-3009 (1993).
237. Lopez-Bueno A, Mateu MG, Almendral JM. High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient host. J. Virol. 77(4), 2701-2708 (2003).
238. Kaufmann B, Lopez-Bueno A, Mateu MG etal. Minute virus of mice, a parvovirus, in complex with the Fab fragment of a neutralizing monoclonal antibody. J. Virol. 81(18), 9851-9858 (2007).
239. Chapman HN, Fromme P, Barty A etal. Femtosecond x-ray protein nanocrystallography. Nature 470(7332), 73-77 (2011).
240. Seibert MM, Ekeberg T, Maia FR etal. Single mimivirus particles intercepted and imaged with an x-ray laser. Nature 470(7332), 78-81 (2011).
241. Yu X, Ge P, Jiang J, Atanasov I, Zhou ZH. Atomic model of CPV reveals the mechanism used by this single-shelled virus to economically carry out functions conserved in multishelled reoviruses. Structure 19(5), 652-661 (2011).
242. Peng L, Ryazantsev S, Sun R, Zhou ZH. Three-dimensional visualization of gammaherpesvirus life cycle in host cells by electron tomography. Structure 18(1), 47-58 (2010).
243. Delano WL. The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC (2002).
244. Pettersen EF, Goddard TD, Huang CC etal. UCSF Chimera -a visualization system for exploratory research and analysis. J. Comput. Chem. 25(13), 1605-1612 (2004).
245. Xiao C, Rossmann MG. Interpretation of electron density with stereographic roadmap projections. J. Struct. Biol. 158(2), 182-187 (2007).